Characterization of ochratoxin A transport by human organic anion transporters.

Article Details

Citation

Jung KY, Takeda M, Kim DK, Tojo A, Narikawa S, Yoo BS, Hosoyamada M, Cha SH, Sekine T, Endou H

Characterization of ochratoxin A transport by human organic anion transporters.

Life Sci. 2001 Sep 21;69(18):2123-35.

PubMed ID
11669456 [ View in PubMed
]
Abstract

The purpose of this study was to investigate the characteristics of ochratoxin A (OTA) transport by multispecific human organic anion transporters (hOAT1 and hOAT3, respectively) using the second segment of proximal tubule (S2) cells from mice stably expressing hOAT1 and hOAT3 (S2 hOAT1 and S2 hOAT3). S2 hOAT1 and S2 hOAT3 exhibited a time- and dose-dependent, and a saturable increase in uptake of [3H]-OTA, with apparent Km values of 0.42 microM (hOAT1) and 0.75 microM (hOAT3). These OTA uptakes were inhibited by several substrates for the OATs. Para-aminohippuric acid (PAH), probenecid, piroxicam, octanoate and citrinin inhibited [3H]-OTA uptake by hOAT1 and hOAT3 in a competitive manner (Ki = 4.29-3080 microM), with the following order of potency: probenecid > octanoate > PAH > piroxicam > citrinin for hOAT1; probenecid > piroxicam > octanoate> citrinin > PAH for hOAT3. These results indicate that hOAT1, as well as hOAT3, mediates a high-affinity transport of OTA on the basolateral side of the proximal tubule, but hOAT1- and hOAT3-mediated OTA transport are differently influenced by the substrates for the OATs. These pharmacological characteristics of hOAT1 and hOAT3 may be significantly related with the events in the development of OTA-induced nephrotoxicity in the human kidney.

DrugBank Data that Cites this Article

Drug Targets
DrugTargetKindOrganismPharmacological ActionActions
ProbenecidSolute carrier family 22 member 6ProteinHumans
Yes
Inhibitor
Details
ProbenecidSolute carrier family 22 member 8ProteinHumans
Yes
Inhibitor
Details
Drug Transporters
DrugTransporterKindOrganismPharmacological ActionActions
Aminohippuric acidSolute carrier family 22 member 6ProteinHumans
Unknown
Substrate
Inhibitor
Details
Aminohippuric acidSolute carrier family 22 member 8ProteinHumans
Unknown
Substrate
Inhibitor
Details
AspartameSolute carrier family 22 member 6ProteinHumans
Unknown
Inhibitor
Details
AspartameSolute carrier family 22 member 8ProteinHumans
Unknown
Inhibitor
Details
BenzylpenicillinSolute carrier family 22 member 6ProteinHumans
Unknown
Inhibitor
Details
BenzylpenicillinSolute carrier family 22 member 8ProteinHumans
Unknown
Substrate
Inhibitor
Details
Caprylic acidSolute carrier family 22 member 6ProteinHumans
Unknown
Inhibitor
Details
Caprylic acidSolute carrier family 22 member 8ProteinHumans
Unknown
Inhibitor
Details
CimetidineSolute carrier family 22 member 6ProteinHumans
Unknown
Substrate
Inhibitor
Details
CimetidineSolute carrier family 22 member 8ProteinHumans
Unknown
Substrate
Inhibitor
Details
IndomethacinSolute carrier family 22 member 6ProteinHumans
Unknown
Substrate
Inhibitor
Details
IndomethacinSolute carrier family 22 member 8ProteinHumans
Unknown
Inhibitor
Details
PiroxicamSolute carrier family 22 member 6ProteinHumans
Unknown
Inhibitor
Details
PiroxicamSolute carrier family 22 member 8ProteinHumans
Unknown
Inhibitor
Details
ProbenecidSolute carrier family 22 member 6ProteinHumans
Unknown
Substrate
Inhibitor
Details
ProbenecidSolute carrier family 22 member 8ProteinHumans
Unknown
Inhibitor
Details